Evaluating Early Aspirin Treatment After Intravenous Thrombolysis in Acute Ischemic Stroke Patients A Multicenter, Randomized, Placebo-Controlled Trial
Led by Capital Medical University · Updated on 2026-09-24
1184
Participants Needed
119
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks.
Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis.
During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
CONDITIONS
Brief Title
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
Research Team
X
XunMing Ji, MD, PD
W
Wenbo Zhao, MD, PD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Acute ischemic stroke treated with intravenous thrombolysis within 4.5 hours of symptom onset or last known well time
Ability to receive study treatment within 3 hours of starting intravenous thrombolysis
Residual NIH Stroke Scale score greater than 5 points one hour after thrombolysis and before randomization
Informed consent provided by patient or authorized representative
You will not qualify if you...
Stroke caused by large vessel occlusion confirmed by imaging or planned for endovascular treatment
Intracranial hemorrhage after thrombolysis confirmed by imaging
Definite or suspected cardioembolic stroke
Stroke caused by other specific disorders such as moyamoya disease or artery dissection
Use of antiplatelet therapy within 1 week before stroke or certain anticoagulants within 48 hours before stroke
History of moderate or severe ischemic stroke with lasting disability
Pre-stroke modified Rankin scale score greater than 1
Severe consciousness disturbance with NIHSS level of consciousness score 2 or higher
Large infarct area shown on imaging after thrombolysis
Known contraindications to antiplatelet therapy including bleeding disorders
Allergy to aspirin
Expected need for anticoagulant therapy during study
Presence of severe illnesses such as cancer, kidney or liver failure, or severe heart failure
Severe complications expected to limit survival to less than 6 months
Inability to follow up
Presence of dementia, psychiatric, or other neurological disorders complicating follow-up
Current participation in another treatment study with ongoing follow-up
Other conditions considered unsuitable by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Initial treatment period around thrombolysis
Participants receive either oral aspirin or placebo within 3 hours of starting intravenous thrombolysis, along with the best standard medical care according to guidelines.
1 visit at treatment initiation and close monitoring
Follow-up
Duration - 90 days
Participants are monitored for neurological recovery and safety outcomes over a 90-day period after stroke.
Scheduled assessments at 30 and 90 days post-stroke
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase II Study of MT200605 for Treating Acute Ischemic Stroke
Randomized, Double-Blind, Placebo-Controlled Trial in Adults 18 to 80 Years
Evaluating Two Dosages of Bevifibatide Injection for Treating Acute Ischemic Stroke Without Large Vessel Blockage in Adults
Study to Test Safety and Effectiveness of Super-Bore 87F Aspiration Catheters
for Treating Acute Blockages in Large Brain Arteries
Evaluation of B2065 Cell Injection Safety and Preliminary Effectiveness in Adults with Acute Ischemic Stroke
Randomized, Double-Blind Trial Evaluating Safety and Effects of TAK-755 Compared to Placebo in Adults with Acute Ischemic Stroke
Open-Label Study Evaluating Multiple Doses of LT3001 to Restore Arterial Blood Flow in Adults With Acute Ischemic Stroke
Evaluating Intravenous Tenecteplase Versus Standard Care for Adults With Acute Ischemic Stroke More Than 4.5 Hours After Last Known Well
Multicenter Registry Study of Endovascular Treatment for Acute Ischemic Stroke
Clinical Study of Stroke Recurrence and Characteristics in Patients With Acute Ischemic Stroke and Active Cancer A Multicenter Prospective Observational Study
Treatment of Acute Stroke Caused by Carotid Artery Bifurcation Using Micronet-Covered CGuard Stent with Flow Reversal and Thrombus Removal
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Bart M Demaerschalk, Dawn O Kleindorfer, Opeolu M Adeoye...
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
William J Powers, Alejandro A Rabinstein, Teri Ackerson...